Gilead Sciences CEO Daniel O'Day receives $29M in 2019
Gilead Sciences reports 2019 executive compensation
By ExecPay News
Published: March 24, 2020
Gilead Sciences reported fiscal year 2019 executive compensation information on March 24, 2020.
In 2019, nine executives at Gilead Sciences received on average a compensation package of $8.7M, a 20% increase compared to previous year.
Average pay of disclosed executives at Gilead Sciences
Daniel P. O'Day, Chief Executive Officer, received $29M in total. 53% of O'Day's compensation, or $16M, was in stock awards. O'Day also received $5.7M in bonus, $3.1M in non-equity incentive plan, $3M in option awards, $1.3M in salary, as well as $545K in other compensation.
For fiscal year 2019, the median employee pay was $173,264 at Gilead Sciences. Therefore, the ratio of Daniel P. O'Day's pay to the median employee pay was 168 to one.
Johanna Mercier, Chief Commercial Officer, received a compensation package of $8M. 47% of the compensation package, or $3.8M, was in stock awards.
Gregg H. Alton, Chief Executive Officer, earned $7.8M in 2019, a 60% increase compared to previous year.
Laura J. Hamill, Former Executive Vice President Worldwide Commercial Operations, received $7.7M in 2019, which decreases by 26% compared to 2018.
Robin L. Washington, Chief Financial Officer, earned $6.3M in 2019, which is about the same as previous year.
Andrew D. Dickinson, Chief Financial Officer, received $5.6M in 2019.
John G. McHutchison, Chief Scientific Officer, earned $5.4M in 2019, a 25% decrease compared to previous year.
Brett A. Pletcher, General Counsel, received $5M in 2019.
Merdad V. Parsey, Chief Medical Officer, earned $3.1M in 2019.
Related executives
Daniel O'Day
Gilead Sciences
Chief Executive Officer
Andrew Dickinson
Gilead Sciences
Chief Financial Officer
Johanna Mercier
Gilead Sciences
Chief Commercial Officer
Merdad Parsey
Gilead Sciences
Chief Medical Officer
Brett Pletcher
Gilead Sciences
General Counsel
Gregg Alton
Gilead Sciences
Chief Executive Officer
Robin Washington
Gilead Sciences
Chief Financial Officer
Laura Hamill
Gilead Sciences
Former Executive Vice President Worldwide Commercial Operations
You may also like
Source: SEC filing on March 24, 2020.